The Dutch enzyme and ingredients group DSM has acquired the Danish biotech company Glycom in a transaction valuing Glycom at EUR 765 million.
Glycom was formed in 2005 by glucose research scientists and chemists from the Technical University of Denmark (DTU). The company is the global market leader within the development and manufacture of HMOs. HMOs are small fibres that exist in mother's milk and that help ensure a healthy intestinal flora in children and adults. The fibres are believed to play key roles in many of the health-promoting effects of mother's milk. In 2016, Glycom was the first company in the world to have an HMO approved for use in infant formula.
Glycom is based in Hørsholm, Denmark, and, today, has research scientists and developers from 15 different countries.
DSM is a world-leading group within the development and manufacture of enzymes and ingredients. The company has more than 23,000 employees.
We advise in connection with the largest and most complex transactions on the market.
Read a selection of our cases here.
Read more about our advisory services on M&A.